Emerging data suggest this peptide, a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may represent a significant step forward for body treatment. Early clinical trials have shown considerable losses in abdominal tissue, potentially surpassing current weight-loss treatments. However , further evalua